Table 1.
Clinical and demographic characteristics of the study cohort.
| MS patients | Healthy Control | |
|---|---|---|
| Gender, n (%) | ||
| Male | 29 (44.6) | 4 (44.4) |
| Female | 36 (55.4) | 5 (55.6) |
| Age, years | ||
| Mean age (±SD) | 39.6 (±10.3) | 43.1 (±9.5) |
| Median age | 40 | 41 |
| IQR 25–75 | 14.5 | 11 |
| MS type, n (%) | ||
| RRMS | 63 (96.9) | |
| SPMS | 2 (3.1) | |
| EDSS, mean (range) | 1.9 (0 - 6.5) | |
| Disease duration, mean (±SD), years | 8.2 (±6.1) | |
| DMTs duration, mean (±SD), months | 47 (±40) | |
| DMTs, n (%) | ||
| Natalizumab | 13 (20.0) | |
| Dimethyl fumarate | 11 (16.9) | |
| Interferon β1-a | 10 (15.4) | |
| Fingolimod | 9 (13.8) | |
| Ocrelizumab | 8 (12.3) | |
| Cladribine | 6 (9.2) | |
| Teriflunomide | 5 (7.7) | |
| Glatiramer acetate | 3 (4.6) |
DMTs: Disease modifying therapy; EDSS: Expanded disability status scale; IQR: Interquartile range; MS: Multiple sclerosis; RRMS: Relapsing remitting multiple sclerosis; SD: Standard deviation;SPMS: Secondary progressive multiple sclerosis.